Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Zenas BioPharma (NASDAQ: ZBIO) said management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 1:30 p.m. ET. A live webcast and archived replay will be available under Events and Presentations in the Investor & Media Relations section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
On the day this news was published, ZBIO gained 4.77%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -8.3% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $54M to the company's valuation, bringing the market cap to $1.19B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ZBIO gained 8.65% while key biotech peers were mixed: AVXL (-2.44%), GERN (-1.31%), PRAX (-0.31%), SANA (-3.92%) and QURE (+10.76%). Moves do not indicate a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Inducement grant | Neutral | +3.6% | Stock option inducement grant for a new employee under Nasdaq Rule 5635(c)(4). |
| Jan 05 | Phase 3 results | Positive | -51.9% | Obexelimab met primary and key secondary endpoints in Phase 3 INDIGO trial in IgG4-RD. |
| Dec 19 | Inducement grants | Neutral | +17.1% | Equity inducement option grants totaling 300,000 shares to new employees. |
| Dec 15 | Partner trial win | Positive | -19.7% | Partner InnoCare achieved primary endpoint in Phase 2b orelabrutinib SLE study. |
| Nov 12 | Earnings and update | Mixed | +1.7% | Q3 2025 results with clinical progress, major financings and going-concern disclosure. |
Recent major clinical wins have sometimes been followed by sharp negative price reactions, while smaller corporate or financing updates showed modest positive or volatile responses.
Over the last few months, ZBIO has reported key clinical and financing milestones. Positive Phase 2 and Phase 3 results for obexelimab and orelabrutinib were noted on Oct 27, 2025 and Jan 5, 2026, yet the stock moved -51.86% after the positive Phase 3 INDIGO data. Inducement grant announcements on Dec 19, 2025 and Jan 16, 2026 saw moderate gains of 17.1% and 3.57%. Q3 2025 earnings on Nov 12, 2025 brought a smaller 1.7% rise. Today’s conference appearance fits the pattern of corporate updates rather than major data catalysts.
Regulatory & Risk Context
An effective S-3ASR shelf filed on Oct 8, 2025 includes an at-the-market equity program for up to $200,000,000 of common stock via Jefferies, giving management flexibility to raise capital alongside ongoing clinical development.
Market Pulse Summary
This announcement highlights Zenas BioPharma’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 at 1:30 p.m. ET, giving management a platform to update investors. In context, the company recently reported major Phase 3 and Phase 2 trial results, significant financings, and filed an effective shelf with a $200,000,000 ATM program. Investors may focus on whether the presentation adds clarity on clinical timelines, funding plans, and previously disclosed going‑concern risks.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET.
A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
FAQ
When will Zenas BioPharma (ZBIO) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
How can investors access the Zenas BioPharma (ZBIO) webcast and replay for the February 11, 2026 presentation?
What will Zenas BioPharma management cover during the ZBIO presentation on February 11, 2026?
Will Zenas BioPharma (ZBIO) release new clinical data at the Guggenheim summit presentation?
